Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Top Cited Papers
Open Access
- 6 April 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (17), 9490-9496
- https://doi.org/10.1073/pnas.2004168117
Abstract
Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 109/L vs. 0.76 × 109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.Keywords
Funding Information
- Key Project of Ministry of Science and Technology of China (2020YFC0841800)
This publication has 30 references indexed in Scilit:
- Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, SpainThe Lancet. Respiratory Medicine, 2015
- Dengue Antibody-Dependent Enhancement: Knowns and UnknownsMicrobiology Spectrum, 2014
- Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteinsBiochemical and Biophysical Research Communications, 2014
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Transfusion‐related acute lung injury (TRALI): a clinical review with emphasis on the critically illBritish Journal of Haematology, 2009
- Treatment with Convalescent Plasma for Influenza A (H5N1) InfectionThe New England Journal of Medicine, 2007
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007
- Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospitalJournal of Antimicrobial Chemotherapy, 2005
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004